ClinicalTrials.gg
TerminatedNCT03290053CE-5SUpdated May 11, 2018

Contrast Enhanced Sonothrombolysis and Sonolysis in Stroke - a Swedish Study (CE-5S)

A Phase 3 interventional study of SonoVue and Sodium chloride in Ischemic Stroke, sponsored by Umeå University. Terminated at 1 site in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-05-11.

Sponsored by Umeå University · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Poor inclusion rate \& lack of funding

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies in Ischemic Stroke with a site in Sweden — 7 open to participants now, 12 under way, 2 of them phase 3. Ischemic Stroke · Sweden.

Enrollment
30th of 30
1 · median 630
Started
2017
with 3 others
Phase 3
13 of 43
1 open now
Registered
20th of 43
by date

Among the 43 studies in Ischemic Stroke with a site in Sweden, this one is the 30th largest by enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2017, is one of 13 in phase 3, and was the 20th registered.

Ischemic Stroke

2,625 studies on the registry are indexed under Ischemic Stroke; 982 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 43 studies in Ischemic Stroke with a site in Sweden are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 402 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Ischemic Stroke with a site in Sweden, or all of them as a file.
02

Study summary

Patients with acute ischemic stroke in anterior circulation within 4,5 hours of symptom onset, has a bone window and Trombolysis In Brain Ischemia (TIBI) \<=4 in a relevant artery eligible. Both patients receiving thrombolysis and those who do not due to contraindications such as anticoagulation or recent surgery are enrolled, but into different study arms (CE-5S A for thrombolysis and B for non-thrombolysis); the decision to treat with thrombolysis or not is done according to clinical routine.

All included patients are randomized to receive transcranial ultrasound and SonoVue-infusion or sham-ultrasound and placebo; i.e. in CE-5S A, contrast enhanced sonothrombolysis is compared to thrombolysis and in CE-5S B, contrast enhanced sonolysis is compared with conservative management.

Main outcome is improvement in National Institute of Health Stroke Scale (NIHSS) at 24 hours compared to baseline. Main safety outcome is symptomatic intracerebral haemorrhage.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients ≥18 years with acute ischaemic stroke in the anterior circulation, who has given written consent for his/her participation to the study.
  • Remaining neurological deficit that is ≥1 NIHSS points, sufficient to warrant treatment with tPA (not taking possible into account) and is severe enough that possible improvement is clearly analysable
  • Treatment \<4½ hours of symptom onset or of waking up in the morning with symptoms
  • Sufficient bone window for acceptable or better acquisition of flow information with ultrasound with TIBI ≤ 4 in the symptomatic artery
  • In cases with women of Childbearing Capacity (WOCBC): Only if willing to comply with effective methods during the course of the trial. Acceptable methods are such as oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double-barrier methods (for example, condom and spermicide), intrauterine device (IUD), hormonal IUD

Exclusion criteria

Exclusion Criteria:

  • Patients with premorbid modified Rankin Scale (mRS) score ≥3;
  • Patients for whom a complete NIHSS cannot be obtained;
  • Hemiplegic migraine with no arterial occlusion on baseline Computed Tomography of brain (CT);
  • Seizure at stroke onset and no visible occlusion on baseline CT;
  • Intracranial haemorrhage on baseline CT;
  • Clinical presentation suggesting subarachnoid haemorrhage even if baseline CT is normal;
  • Large areas of hypodense ischaemic changes on baseline CT;
  • Pregnancy or breast-feeding, pericarditis; sepsis; any other serious medical illness likely to interact with treatment; confounding pre-existent neurological or psychiatric disease; unlikely to complete follow-up; any drug \<14 days;
  • Inability to provide sufficiently clearly that the study physician can be convinced that informed consent has been given by the patient - such as severe aphasia or coma.

Specific sonothrombolysis exclusion criteria

  • known /allergy to SonoVue;
  • recent or unstable coronary ischemia or resting angina \<7 days;
  • acute cardiac insufficiency, cardiac insufficiency class III/IV; serious cardiac arrhythmias;
  • any right-left-shunt; severe pulmonary hypertension; uncontrolled hypertension;
  • moderate to severe (COPD; baseline O2 saturation \<80%);
  • acute respiratory distress syndrome (ARDS);
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    CE-5S A: Treatment arm

    Gets thrombolysis, transcranial ultrasound on the flow limitation and SonoVue infusion

    Drug: SonoVue · Procedure: Transcranial Ultrasound

  • Sham comparator
    CE-5S A: Control arm

    Gets thrombolysis, sham transcranial ultrasound and placebo (NaCl) infusion

    Drug: Sodium chloride · Procedure: Sham Transcranial Ultrasound

  • Experimental
    CE-5S B: Treatment arm

    Gets NO thrombolysis (due to contraindications), transcranial ultrasound on the flow limitation and SonoVue infusion

    Drug: SonoVue · Procedure: Transcranial Ultrasound

  • Sham comparator
    CE-5S B: Control arm

    Gets NO thrombolysis (due to contraindications), sham transcranial ultrasound and placebo (NaCl) infusion

    Drug: Sodium chloride · Procedure: Sham Transcranial Ultrasound

Interventions

  • DrugContrast agent BR1Studies of Contrast agent BR1Contrast agent BR1 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    SonoVue-infusion over 1 hour

  • DrugSodium chloride

    Placebo

  • ProcedureTranscranial Ultrasound

    Transcranial ultrasound aimed at the blockage

  • ProcedureSham Transcranial Ultrasound

    Placebo - machine is attached, but not active

06

What researchers measure

Primary outcomes

  1. Early clinical Outcome defined as change in NIHSS at 24 hours.

    Change in National NIHSS at 24 hours. Defined reaching of primary endpoint is post-treatment 0 Points and/or improves with \>=4 Points compared to pre-treatment.

    Time frame: 24 hours

Secondary outcomes

  1. Safety: Symptomatic Cerebral Hemorrhage (sICH)

    Assessed with routine post-treatment CT head and requires an accompanied \>=4 Points worsening on NIHSS.

    Time frame: 24-36 hours

  2. Long term outcome defined as residual handicap at Three months

    90-days modified Rankin Scale (mRS) reaching 0-1.

    Time frame: 90 days

07

Study locations

1 site
  • University Hospital
    Umeå, Västerbotten 90821, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Apr 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 21, 2017
StartActual
Nov 28, 2017
Primary completionActual
Apr 18, 2018
CompletionActual
Apr 18, 2018
Last update
May 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03290053
Lead sponsor
Umeå University
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Nov 28, 2017
Primary completion
Apr 18, 2018
Completion
Apr 18, 2018
Last update
May 11, 2018

Study contacts

Elias Johansson, MD, PhD
principal investigator · Umeå University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Contrast agent BR1

Start the discussion